Breast Cancer

Stay updated with news from ASCO’s official conference reporter.
April 27, 2022
Prosigna and the Breast Cancer Index may be used in postmenopausal patients with breast cancer that is node-negative, ER-positive, and HER2-negative.
April 20, 2022
The guideline update recommends pembrolizumab in combination with neoadjuvant chemotherapy, followed by adjuvant pembrolizumab after surgery, for patients with T1cN1-2 to T2-4N0 early-stage TNBC.
April 13, 2022
Approximately one-half of breast cancer survivors receiving a behavioral weight loss intervention, with or without the addition of pharmacotherapy, achieved at least 5% weight loss at 8 weeks.
April 13, 2022
PREDICT appears to accurately predict 5- and 10-year overall survival in a contemporary and more ethnically diverse population of U.S. patients with early-stage breast cancer.
April 13, 2022
Patients with advanced breast cancer derive the same benefits from CDK4/6 inhibitors in a real-world setting as those in randomized phase 3 clinical trials.
March 16, 2022
In response to practice-changing data published within the past 5 years, an Expert Panel convened to update the guidelines and clinical practice considerations for the treatment of hormone receptor (HR)–positive and HR-negative/HER2-negative metastatic breast cancer.
March 10, 2022
The guideline recommends that patients with early-stage breast cancer who are younger than age 70 without significant competing comorbidities should undergo sentinel lymph node biopsy for axillary staging.
March 9, 2022
Fifteen years of studies since the approval of adjuvant trastuzumab have led to effective and more tolerable treatment regimens for patients with HER2-positive breast cancer.
March 3, 2022
HER2-targeted agents are allowing patients with HER2-positive breast cancer to live longer, making the benefit of cytotoxic chemotherapy less clear.
February 23, 2022
Pembrolizumab and chemotherapy improves overall survival compared with chemotherapy alone and represents a new standard of care for patients with treatment-naïve mTNBC whose tumors have a PD-L1 combined positive score of ≥ 10.

This site is intended for healthcare professionals in Europe and Japan only.

The selection of ASCO content on this site was made by the ASCO Publication and Education teams. Springer Healthcare selected the experts for interview. All content is made available solely for educational and informational purposes and personal use only.

© 2022 American Society of Clinical Oncology (ASCO®). All Rights Reserved.

This program is supported by an educational grant from Daiichi Sankyo and brought to you by Springer Healthcare | Contact Us | Privacy Policy

Before you go....

We'd love your feedback!

Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.